AICDA and neoplasm: In this regard, and in contrast with recent data derived from studies based on in vitro and in tumor cell lines46, recent observations have demonstrated that ibrutinib therapy results in a profound reduction in both AID expression and proliferative leukemic fractions in treated patients49.